Literature DB >> 23069012

Endurance training and chronic intermittent hypoxia modulate in vitro salicylate-induced hepatic mitochondrial dysfunction.

A Ascensão1, I O Gonçalves, J Lumini-Oliveira, I Marques-Aleixo, E Dos Passos, S Rocha-Rodrigues, N G Machado, A C Moreira, P J Oliveira, J R Torrella, J Magalhães.   

Abstract

Mitochondrial function is modulated by multiple approaches including physical activity, which can afford cross-tolerance against a variety of insults. We therefore aimed to analyze the effects of endurance-training (ET) and chronic-intermittent hypobaric-hypoxia (IHH) on liver mitochondrial bioenergetics and whether these effects translate into benefits against in vitro salicylate mitochondrial toxicity. Twenty-eight young-adult male rats were divided into normoxic-sedentary (NS), normoxic-exercised (NE), hypoxic-sedentary (HS) and hypoxic-exercised (HE). ET consisted of 1h/days of treadmill running and IHH of simulated atmospheric pressure of 49.3 kPa 5h/days during 5weeks. Liver mitochondrial oxygen consumption, transmembrane-electric potential (ΔΨ) and permeability transition pore induction (MPTP) were evaluated in the presence and absence of salicylate. Aconitase, MnSOD, caspase-3 and 8 activities, SH, MDA, SIRT3, Cyp D, HSP70, and OXPHOS subunit contents were assessed. ET and IHH decreased basal mitochondrial state-3 and state-4 respiration, although no alterations were observed in ΔΨ endpoints evaluated in control mitochondria. In the presence of salicylate, ET and IHH decreased state-4 and lag-phase of ADP-phosphorylation. Moreover, ADP-lag phase in hypoxic was further lower than in normoxic groups. Neither ET nor IHH altered the susceptibility to calcium-induced MPTP. IHH lowered MnSOD and increased aconitase activities. ET and IHH decreased caspase 8 activity whereas no effect was observed on caspase 3. The levels of SIRT3 increased with ET and IHH and Cyp D decreased with IHH. Data suggest that ET and IHH do not alter general basal liver mitochondrial function, but may attenuate some adverse effects of salicylate.
Copyright © 2012 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069012     DOI: 10.1016/j.mito.2012.10.007

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  5 in total

1.  Impact of various exercise modalities on hepatic mitochondrial function.

Authors:  Justin A Fletcher; Grace M Meers; Melissa A Linden; Monica L Kearney; E Matthew Morris; John P Thyfault; R Scott Rector
Journal:  Med Sci Sports Exerc       Date:  2014-06       Impact factor: 5.411

Review 2.  Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease.

Authors:  Jelena Stevanović; Jorge Beleza; Pedro Coxito; António Ascensão; José Magalhães
Journal:  Mol Metab       Date:  2019-11-29       Impact factor: 7.422

3.  Intermittent Hypoxia Rewires the Liver Transcriptome and Fires up Fatty Acids Usage for Mitochondrial Respiration.

Authors:  Jonathan Gaucher; Guillaume Vial; Emilie Montellier; Maëlle Guellerin; Sophie Bouyon; Emeline Lemarie; Véronique Pelloux; Anne Bertrand; Karin Pernet-Gallay; Frederic Lamarche; Anne-Laure Borel; Claire Arnaud; Elise Belaidi; Karine Clément; Diane Godin Ribuot; Judith Aron-Wisnewsky; Jean-Louis Pépin
Journal:  Front Med (Lausanne)       Date:  2022-02-18

Review 4.  The Role of SIRT3 in Exercise and Aging.

Authors:  Lei Zhou; Ricardo Pinho; Yaodong Gu; Zsolt Radak
Journal:  Cells       Date:  2022-08-20       Impact factor: 7.666

5.  Levels of Hepatic Activating Transcription Factor 6 and Caspase-3 Are Downregulated in Mice after Excessive Training.

Authors:  Ana P Pinto; Alisson L da Rocha; Luciana da C Oliveira; Gustavo P Morais; Larissa G de Vicente; Dennys E Cintra; José R Pauli; Leandro P Moura; Eduardo R Ropelle; Adelino S R da Silva
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-26       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.